Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/18403
Title: [18F]-THK5351 PET Imaging in Patients With Semantic Variant Primary Progressive Aphasia.
Authors: Lee, Hyon;Seo, Seongho;Lee, Sang-Yoon;Jeong, Hye Jin;Woo, Sung-Ho;Lee, Kyoung-Min;Lee, Yeong-Bae;Park, Kee Hyung;Heo, Jae-Hyeok;Yoon, Cindy W;Kang, Jae Myeong;Cho, Jaelim;Okamura, Nobuyuki;Furumoto, Shozo;Yanai, Kazuhiko;Na, Duk L;Ido, Tatsuo;Villemagne, Victor L;Noh, Young
Affiliation: Departments of Neurology
Department of Neuroscience, College of Medicine
Neuroscience Research Institute
Department of Neurology, Seoul National University Hospital
Department of Neurology, Seoul Medical Center
Department of Neurology, Inha University School of Medicine, Incheon
Psychiatry
Occupational and Environmental Medicine, Gachon University Gil Medical Center
Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
Department of Pharmacology, Tohoku Medical and Pharmaceutical University
Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine.. Neuroscience Center, Samsung Medical Center, Seoul, Republic of Korea
Department of Molecular Imaging and Therapy, Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Departments of Neurology.. Department of Health Science and Technology, GAIHST, Gachon University
The Florey Institute of Neuroscience and Mental Health, the University of Melbourne, Melbourne, Vic., Australia
Issue Date: Jan-2018
Citation: Alzheimer disease and associated disorders 2018; 32(1): 62-69
Abstract: Semantic variant primary progressive aphasia (svPPA) has been associated with a variety of proteinopathies, mainly transactive response DNA-binding protein, but also with tau and β-amyloid. Recently selective tau tracers for positron emission tomography (PET) have been developed to determine the presence of cerebral tau deposits in vivo. Here, we investigated the topographical distribution of THK5351 in svPPA patients. Five svPPA patients, 14 Alzheimer's disease patients, and 15 age-matched normal controls underwent [F]-THK5351 PET scans, magnetic resonance imaging, and detailed neuropsychological tests. [F]-fluorodeoxyglucose PET was obtained in 3 svPPA patients, whereas the remaining 2 underwent amyloid PET using [F]-flutemetamol. Tau distribution among the 3 groups was compared using regions of interest-based and voxel-based statistical analyses. In svPPA patients, [F]-THK5351 retention was elevated in the anteroinferior and lateral temporal cortices compared with the normal controls group (left>right), and in the left inferior and temporal polar region compared with Alzheimer's disease patients. [F]-THK5351 retention inversely correlated with glucose metabolism, whereas regional THK retention correlated with clinical severity. [F]-flutemetamol scans were negative for β-amyloid. These findings show that [F]-THK5351 retention may be detected in cortical regions correlating with svPPA pathology.
URI: http://ahro.austin.org.au/austinjspui/handle/1/18403
DOI: 10.1097/WAD.0000000000000216
PubMed URL: 29028649
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.